EvoGenix and Absalus Combine Operations

Australian protein therapeutics company EvoGenix Pty Ltd announced a merger with California-based Absalus Inc. to create an integrated company with a primary focus on developing new antibody-based drugs. EvoGenix and Absalus own complementary technologies which, when combined, are capable of streamlining the identification of new antibody drug candidates and improving the development of safe and effective human therapeutic antibodies.
PR Newswire